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Bone-seeking radiopharmaceuticals are frequently used as diagnostic agents in nuclear medicine, because they can detect bone
disorders before anatomical changes occur. Furthermore, their effectiveness in the palliation of metastatic bone cancer pain
has been demonstrated in the clinical setting. With the aim of developing superior bone-seeking radiopharmaceuticals, many
compounds have been designed, prepared, and evaluated. Here, several well-designed bone-seeking compounds used for diagnostic
and therapeutic use, having the concept of radiometal complexes conjugated to carrier molecules to bone, are reviewed.
1. Introduction
For many years, 99mTc-bisphosphonate complexes, 99mTc-
methylenediphosphonate (99mTc-MDP, Figure 1(a)) and
99mTc-hydroxymethylenediphosphonate (99mTc-HMDP,
Figure 1(b)), have been clinically used for nuclear medical
imaging of metastatic bone cancer [1–4], because their high
sensitivity can detect bone metastases before occurrence of
anatomical changes. Bone metastases are characterized as
osteolytic, osteosclerotic, or mixed type of osteolytic and
osteosclerotic; namely, osteolytic or osteosclerotic changes
occur in lesion sites of bone metastases. These anatomical
changes could cause pathologic fractures and severe pain.
It has been known that strontium (Sr) acts as calcium
mimic and accumulates in high osteoblastic activity lesions
since strontium is one of the alkaline earth metals [5]. 89Sr
has a physical half-life of 50.5 days and emits beta particles
with a maximum energy of 1.46MeV (Table 1). Strontium-89
chloride (89SrCl
2
, Metastron) was the first radiopharmaceu-
tical approved for the palliation of metastatic bone pain by
the US Food andDrug Administration (FDA). 89SrCl
2
for the
palliation of metastatic bone pain for breast cancer patients
and prostate cancer patients showed a pain relief rate of 57–
92%. These studies are summarized in reviews [6–9].
Samarium-153 (153Sm) has a physical half-life of 46.3
hours and emits beta particles with a maximum energy of
0.81MeV (20%), 0.71MeV (49%), and 0.64MeV (30%) and
a 28% abundance of gamma rays with energy of 103 keV
(Table 1). 153Sm-ethylenediaminetetramethylene phosphonic
acid (EDTMP, Quadramet) is a complex of 153Sm and
EDTMP (Figure 1(c)), which has high affinity for bone
mineral. 153Sm-EDTMP was approved and has been widely
used in the United States for palliation of metastatic bone
pain. The biodistribution of 153Sm-EDTMP is similar to that
of bone scintigraphic agents such as 99mTc-MDP (methylene
diphosphonate) [10]. Accordingly, it was reported that the
dosimetry of 153Sm-EDTMP could be predicted using 99mTc-
MDP bone scintigraphy [11]. 153Sm-EDTMP showed a pain
relief rate in 62–84% of patients with metastatic bone pain.
These studies are also summarized in reviews [6–8]. Mean-
while, in a study of comparison between the effects of the
89SrCl
2
and 153Sm-EDTMP to patients with bone metastases,
there was no statistical difference in response rates [12].
Zoledronic acid (Zometa), which is a bisphosphonate
compound, has been widely used for the prevention of
skeletal complications. Lam et al. combined zoledronic acid
and 153Sm-EDTMP to treat hormone-refractory prostate
cancer patients [13]. It was concluded that zoledronic acid
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Figure 1: Chemical structures of bisphosphonates analogs (a) MDP, (b) HMDP, (c) EDTMP, and (d) HEDP.






gamma ray (keV, %)
Maximum range
(mm) Main production
Tc-99m 6.02 h None 141 (89%) —
98Mo(n, 𝛾)99Mo
99Mo/99mTc generator
Ga-68 67.6m None 1077 (3%)1899 (89%)∗ —
69Ga(p, 2n)68Ge
68Ge/68Ga generator
Sr-89 50.5 d 1.46 910 (0.01%) 7 88Sr(n, 𝛾)89Sr
Sm-153 1.9 d 0.81 103 (28%) 4 152Sm(n, 𝛾)153Sm
Re-186 3.8 d 1.07 137 (9%) 5
186W(p, n)186Re
185Re(n, 𝛾)186Re









𝛼 energy (Ra-223 has multiple decay to stable nuclide in which 4𝛼 particles are generated during each decay, resulting in high energy deposition (28.2MeV),
with 95% of the energy from the 𝛼 emissions [67].).
‡Ra-223 could be produced from 227Ac/227Th generator and purified using Ac-resin to immobilize 227Ac and 227Th [33].
treatment does not influence 153Sm-EDTMP skeletal uptake
and combined treatment is feasible and safe.
The therapeutic bone-seeking radiopharmaceutical
radium-223 chloride (223RaCl
2
) was approved by FDA
and European Medicines Agency (EMA) in 2013 based on
data from a phase III randomized trial (the Alpharadin
in Symptomatic Prostate Cancer Patients: ALSYMPCA).
Surprisingly, 223RaCl
2
significantly improved overall survival
in patients with castration-resistant prostate cancer with
bone metastases in the ALSYMPCA study [14, 15]. In
addition, because it is the first radiopharmaceutical emitting









are milestones in the development of bone-seeking
radiopharmaceuticals for clinical use (Table 2). Although
developing superior bone-seeking compounds is difficult, we
reviewed the promising well-designed bone-seeking com-
pounds for diagnosis and therapy of bone metastases in basic
research.
Table 2: Radiopharmaceuticals approved for bone metastases by
FDA or EMA.








153Sm-EDTMP (Quadramet) 37MBq/kg Therapy
223RaCl2 (Xofigo) 50 kBq/kg Therapy
2. 99mTc-Complex-Conjugated
Bisphosphonate Compounds Designed to
Overcome Drawbacks of 99mTc-MDP
and 99mTc-HMDP Complexes
Although 99mTc-MDP and 99mTc-HMDPare considered to be
the gold standards for bone scintigraphy agents, they have not

























































































Figure 2: Chemical structures of 99mTc-complex-conjugated bisphosphonate compounds: (a) 99mTc-EC-AMDP, (b) 99mTc-MAG3-HBP, (c)
99mTc-HYNIC-HBP, and (d) 99mTc-HYNIC-AMDP.
yet been optimized from a chemical and pharmaceutical per-
spective, because these complexes are notwell-defined single-
chemical species but are mixtures of short-chain and long-
chain oligomers [16]. Moreover, the phosphonate groups in
99mTc-MDP and 99mTc-HMDP are used both as ligands for
coordination and as carriers to hydroxyapatite (HA) in bone
[17], which may decrease the inherent affinity of MDP and
HMDP for bone. To overcome these drawbacks, a more
logical design strategy has been proposed on the basis of
the conjugation of a stable radiometal complex to a carrier
molecule to bone. This drug design allows the ligand and
carrier function to work independently and effectively.
In 2002, Verbeke et al. described 99mTc-l,l-ethylenedicy-
steine (EC) complex, a renal tracer agent known to have
rapid renal excretion, conjugated to bisphosphonate (99mTc-
EC-AMDP, Figure 2(a)) [18]. 99mTc-EC-AMDP showed faster
blood clearance and a higher bone/blood ratio comparedwith
99mTc-MDP in animal experiments.
In 2006, we reported 99mTc-mercaptoacetylglycylglycylg-
lycine- (MAG3-) conjugated bisphosphonate (99mTc-MAG3-
HBP, Figure 2(b)) and 99mTc-6-hydrazinonicotinic acid
(HYNIC) with tricine and 3-acetylpyridine as coligands
conjugated to bisphosphonate (99mTc-HYNIC-HBP,
Figure 2(c)) [19]. In in vitro HA binding experiments,
the binding rates of 99mTc-MAG3-HBP and 99mTc-HYNIC-
HBP to HA were higher than those of 99mTc-HMDP. In
a biodistribution study in rats, 99mTc-MAG3-HBP and
99mTc-HYNIC-HBP showed higher accumulation in bone
compared with 99mTc-HMDP reflecting the in vitro findings.
The blood clearance of 99mTc-MAG3-HBP was delayed
because of the high rate of protein binding in blood and
the bone/blood ratio of 99mTc-MAG3-HBP was lower than
that of 99mTc-HMDP. In contrast, the blood clearance of
99mTc-HYNIC-HBP was as rapid as that of 99mTc-HMDP
and its bone/blood ratio was higher.
Liu et al. reported findings on 99mTc-HYNIC-conjugated
bisphosphonate (99mTc-HYNIC-AMDP, Figure 2(d)) in 2011
[20]. The authors found that 99mTc-HYNIC-AMDP had a
higher bone uptake and higher bone/blood and bone/muscle
ratios at an early time point after injection as compared with
99mTc-MDP. In that study, 99mTc-HYNIC-AMDP showed
favorable biodistribution as a bone-seeking agent, but the
bone accumulation of 99mTc-MDP, a bone scintigraphy agent
as a control, appeared to be too low. Two tricine molecules
are used as coligands in 99mTc-HYNIC-AMDP. However, as
it has been reported, the complex [99mTc](HYNIC)(tricine)
2
is not stable and exists in multiple forms, and the pharma-
cokinetics could be affected by the exchange reaction between
tricine and protein in the plasma and tissues [21–23]. The
pharmacokinetics of 99mTc-HYNIC-AMDPmaybe improved
by exchanging one tricine molecule for another molecule,
such as one of the pyridine derivatives.
Palma et al. described 99mTc-tricarbonyl complex, which
is anchored by a pyrazolyl- (Pz-) containing ligand, conju-








PAM)], Figures 3(a)–3(c)) [24, 25]. The structures of these
technetium complexes were confirmed by reversed phase
(RP) HPLC analyses. The identical retention time as the cor-
responding nonradioactive rhenium (Re) complexes revealed














































































(PzNN-ALN)], (c) [99mTc (CO)
3
(PzNN-PAM)], and (d) 99mTc (CO)
3
-DPA-alendronate.
the structural analogy. Although [99mTc(CO)
3
(PzNN-BP)]
showed moderate bone uptake, the uptake was lower than






was high and comparable to that of 99mTc-MDP. The





(PzNN-PAM)] were higher than that
of 99mTc-MDP at 4 hours after injection because of their fast
clearance.Thedifference in bone accumulation among 99mTc-
tricarbonyl complex-conjugated bisphosphonate compounds
could be derived from the introduction of a hydroxyl group
at the central carbon of the bisphosphonate because bisphos-
phonates containing the hydroxyl group have been reported
to have higher affinity for bone minerals [26–28].
In 2009, De Rosales et al. described 99mTc-tricarbonyl
complex-conjugated bisphosphonate that has the structure
similar to that of [99mTc(CO)
3
(PzNN-ALN)] but with dipi-
colylamine (DPA) was used as a chelation site (99mTc(CO)
3
-
DPA-alendronate, Figure 3(d)) [29]. In vitro study showed
that 99mTc(CO)
3
-DPA-alendronate had higher affinity forHA
than 99mTc-MDP. In animal experiments, 99mTc(CO)
3
-DPA-
alendronate showed high uptake in bone, comparable to
99mTc-MDP.
As mentioned above, certain 99mTc-complex-conjugated
bisphosphonate compounds have shown favorable biodis-
tribution as bone imaging agents and higher bone/blood
ratios compared with those of 99mTc-MDP or 99mTc-HMDP.
Consequently, these results suggest that the strategy of devel-
oping stable 99mTc-complex-conjugated bisphosphonates is
promising.
3. Radiogallium-Complex-Conjugated
Bisphosphonate Compounds as Bone
Imaging Agents for Positron Emission
Tomography (PET)
68Ga is a practical and interesting radionuclide for clinical
PET because of its radiophysical properties, particularly as
a 68Ge/68Ga generator-produced radionuclide has a half-life
(𝑇
1/2
) of 68 minutes (Table 1) [30]. It does not require an
on-site cyclotron and can be eluted on demand. Indeed, in
principle, the long half-life of the parent nuclide 68Ge (𝑇
1/2
=
270.8 days) provides a generator with a long lifespan.
The above-mentioned drug design concept, which is a
stable complex-conjugated bisphosphonate, could also be
applicable to gallium complexes. With the aim of developing
a superior bone imaging PET tracer, some types of radiogal-
lium complex-conjugated bisphosphonate compounds have
been reported.
In 2010, Fellner et al. reported a human study of
68Ga-DOTA-conjugated bisphosphonate (68Ga-BPAMD,
Figure 4(a)), containing 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) as a ligand for gallium [31].
68Ga-BPAMD showed high uptake in osteoblastic metastases
lesions in a patient with prostate cancer (Figure 5). The
maximal standardized uptake value (SUVmax) was 77.1 and
62.1 in the 10th thoracic and L2 vertebra for 68Ga-BPAMD
compared with respective values of 39.1 and 39.2 for 18F-
fluoride, which is a typical bone imaging agent for PET
(Table 2), respectively. In 2012, Fellner et al. reported the
findings of basic experiments on 68Ga-BPAMD using
𝜇-PET with bone metastasis rat model [32]. 68Ga-BPAMD








































































































Figure 4: Chemical structures of precursors of 67/68Ga complex-conjugated bisphosphonate compounds: (a) BPAMD, (b) BPAPD, (c) BPPED,
(d) DOTA-Bn-SCN-HBP, and (e) NOTA-BP.
(a) (b) (c)
Figure 5: 68Ga-BPAMDwas injected intravenously into a patient with extensive bonemetastases of prostate cancer. 68Ga-BPAMD [maximum
intensity projection (MIP) 50min after injection (p.i.), 462MBq] revealed intense accumulation inmultiple osteoblastic lesions in the central
skeleton, ribs, and proximal extremities: (a) = coronal PET, (b) = sagittal PET/CT. For comparison, (c) shows 18F-fluoride PET (sagittal, MIP
90min p.i., 270 MBq). With kind permission from Springer Science+Business Media: Eur J Nucl Med Mol Imaging, PET/CT imaging of
osteoblastic bone metastases with 68Ga-bisphosphonates: first human study, 37, 2010, 834, Fellner et al.
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highly accumulated in metastatic bone lesions compared
with healthy bone in the same animal (contrast factor =
3.97 ± 1.82). The same research group further reported
68Ga-DOTA-conjugated bisphosphonate derivatives, 68Ga-
BPAPD and 68Ga-BPPED (Figures 4(b) and 4(c)) in 2013
[33]. The phosphinate-conjugated bisphosphonate 68Ga-
BPPED showed higher accumulation in bone compared
with 68Ga-BPAMD and 68Ga-BPAPD, amide-conjugated
bisphosphonates. The presence of phosphinate may
contribute to an additional binding to HA, leading to
higher accumulation in bone.
In 2011, we also reported 67Ga-DOTA complex-
conjugated bisphosphonate (67Ga-DOTA-Bn-SCN-HBP,
Figure 4(d)) [34]. Although the aim was to develop a
superior 68Ga-labeled bone imaging agent for PET, in the
initial basic studies 67Ga was used because of its longer
half-life. In biodistribution experiments in normal mice,
67Ga-DOTA-Bn-SCN-HBP rapidly and highly accumulated
in bone but was rarely observed in tissues other than bone. As
a result, the bone/blood ratio of 67Ga-DOTA-Bn-SCN-HBP
was comparable to that of 99mTc-HMDP, which is a gold
standard for a bone scintigraphy agent.
Furthermore, in 2011, Suzuki et al. reported 68Ga-NOTA-
conjugated bisphosphonate, containing 1,4,7-triazacyclon-
onane-1,4,7-triacetic acid (NOTA) as a ligand for gallium
(68Ga-NOTA-BP, Figure 4(e)) [35]. In biodistribution exper-
iments using Wistar rats, 68Ga-NOTA-BP showed faster
clearance and a higher bone/blood ratio than 99mTc-MDPand
18F-fluoride. Moreover, in PET study using a mouse model of
bone metastasis, 68Ga-NOTA-BP showed high accumulation
of radioactivity in osteolytic lesions in the tibia.
These results suggest that the drug design concept of radio
gallium complex-conjugated bisphosphonate could be useful
for the development of 68Ga PET imaging agents for bone
disorders such as bone metastases.
4. Re-Complex-Conjugated Bisphosphonate
for Palliation of Bone Metastases
Gamma ray emitter radionuclide and positron emitter
radionuclide-labeled bone-seeking agents are used for the
diagnosis of bone metastases. A prominent symptom caused
by bone metastases is pain, which has a significant impact
on the patients’ quality of life. Bone-seeking agents labeled
with high-energy beta particle emitter radionuclides and
alpha particle emitter radionuclides are used for palliation
of pain caused by bone metastases. Rhenium, which has
similar chemical properties to technetium, because they are
members of family VIIA of the periodic table, has two
useful radionuclides, 186Re and 188Re, which are useful for
radionuclide therapy [36]. Both rhenium radionuclides emit
not only beta particles for therapy but also gamma rays, which
are suitable for diagnoses: 186Re (𝑇
1/2
= 3.78 days, 𝛽−max =





max = 2.12MeV, 𝛾 = 155 keV) (Table 1). In addition,
188Re has a further advantage for clinical use because it
is obtained from an in-house alumina-based 188W/188Re
generator, similar to a 99Mo/99mTc generator [37].
When considering the use of rhenium in bone-seeking
agents for palliation, similar to 99mTc-MDP and 99mTc-
HMDP, it is known that rhenium coordinates with some
bisphosphonate derivatives. 186/188Re-1-hydroxyethylidene-
1,1-diphosphonate (186/188Re-HEDP, Figure 1(d)), which has
high affinity for bone, has been prepared and used for clinical
research [9, 38, 39]. Although the chemical properties of
rhenium are similar to those of technetium as mentioned
above, rhenium is more easily oxidized than technetium
[40], and it has been reported that 186Re-HEDP is not as
stable as 99mTc-bisphosphonate complexes [41]. Some studies
reported that 186Re-HEDP showed unexpected gastric uptake
in patients with bonemetastases [42, 43].Thismay be derived
from the accumulation of free rhenium (perrhenate: ReO
4
−)
in the stomach due to the instability of 186Re-HEDP [40,
44]. Moreover, as with 99mTc-MDP and 99mTc-HMDP, the
phosphonate groups in 186/188Re-HEDP are used as both
ligands for coordination and as carrier to HA in bone, which
may decrease the inherent affinity of HEDP for bone.
To overcome these problems, designing a stable 186/188Re-
complex-conjugated bisphosphonate would be useful.
Therefore, we studied 186Re-monoaminemonoamidedithiol-
(MAMA-) and 186Re-mercaptoacetylglycylglycylglycine-
(MAG3-) conjugated bisphosphonate compounds (186Re-
MAMA-BP, 186Re-MAMA-HBP, and 186Re-MAG3-HBP:
Figures 6(a)–6(c)) and reported their findings in 2004,
2006, and 2005, respectively [28, 45, 46]. In an in vitro
stability experiment in buffer solution, the Re-complex-
conjugated bisphosphonate compounds, 186Re-MAMA-
HBP, 186Re-MAMA-BP, and 186Re-MAG3-HBP, were
more stable than 186Re-HEDP. In the biodistribution
experiments performed in normal mice, 186Re-MAMA-
HBP, 186Re-MAMA-BP, and 186Re-MAG3-HBP showed
lower accumulation of radioactivity in stomach compared
with 186Re-HEDP. This result indicates that the drug
design of Re-complex-conjugated bisphosphonates enabled
better stability in vitro and in vivo. Of 186Re-complex-
conjugated bisphosphonate compounds, 186Re-MAG3-HBP
showed the most favorable biodistribution characteristics
as bone-seeking radiopharmaceuticals such as high and
selective bone accumulation, based on high hydrophilicity
(log 𝑃 value: −2.68 ± 0.01) and the introduction of a
hydroxyl group to the central carbon of the bisphosphonate
structure. Previous studies suggested that the hydroxyl group
affects affinity for bone minerals [26, 27]. We evaluated
the therapeutic potential of 186Re-MAG3-HBP for the
palliation of metastatic bone pain using an animal model
of bone metastasis [47]. The planar image of 186Re-MAG3-
HBP showed high accumulation of radioactivity in bone
metastasis lesion. 186Re-MAG3-HBP was more effective for
palliation and was compared with 186Re-HEDP using the
hind paw withdrawal response to stimulation with von Frey
filaments. Moreover, although 186Re-HEDP did not affect
tumor growth, 186Re-MAG3-HBP significantly inhibited
tumor growth.























































































Figure 6: Chemical structures of 186/188Re-complex-conjugated bisphosphonate compounds: (a) 186Re-MAMA-BP, (b) 186Re-MAMA-HBP,
(c) 186Re-MAG3-HBP, (d) [186Re]CpTR-Gly-APD, and (e) 188Re(CO)
3
-DPA-alendronate.
In 2007, Uehara et al. reported [186Re]CpTR-Gly-APD
(Figure 6(d)), which is a tricarbonyl [186Re][(cyclopentadie-
nylcarbonyl amino)-acetic acid] rhenium complex ([186Re]
CpTR-Gly)-conjugated bisphosphonate [48]. [186Re]CpTR-
Gly-APD showed characteristics superior to those of 186Re-
HEDP, such as higher stability in plasma, a higher binding
rate for HA, higher bone accumulation, and lower plasma
protein binding. When [186Re]CpTR-Gly-APD with HEDP
(9.0mg/kg) was administered to mice, the accumulation of
radioactivity in bone significantly decreased and the blood
clearance was delayed. Therefore, the authors concluded
that the specific activity of 186Re-labeled bisphosphonate
compounds is very important to bone accumulation and
blood clearance.
In the 99mTc-complex-conjugated bisphosphonate
session, 99mTc(CO)
3
-DPA-alendronate has been discussed
above. Using the same ligand, in 2010, De Rosales et al.
reported 188Re(CO)
3
-DPA-alendronate (Figure 6(e)) [49].
188Re(CO)
3
-DPA-alendronate can easily be synthesized with
high specific activities and high yields (≥96%). 188Re(CO)
3
-
DPA-alendronate showed higher stability in vitro compared
with 188Re-HEDP, which oxidized to 188ReO
4
− (up to




biodistribution of radioactivity than 188Re-HEDP; that
is, 188Re(CO)
3
-DPA-alendronate highly accumulated in
metabolically active bone, such as the joints with low
soft-tissue uptake.
These results indicate that the concept of the stable 186Re-
complex-conjugated bisphosphonates could be more useful
and that novel 186Re-complex-conjugated bisphosphonate
complexes could be attractive candidates as palliative agents
in metastatic bone pain.
5. Aspartic Acid Peptides as Carriers of
Radionuclides to Bone
Several major noncollagenous bone proteins, such as osteo-
pontin and bone sialoprotein, have repeating sequences of
acidic amino acids (Asp or Glu) in their structures, offering
potential HA binding sites [50–52]. It has been reported that
polyglutamic and polyaspartic acids have a high affinity for
HA and could be used as carriers for drug delivery to bone
[53–55].
In 2013, Yanagi et al. reported 99mTc-complex-conjugated
aspartic acid (Asp) peptides [56].They selected EC as a ligand
to prepare stable technetium complexes, conjugated with one




















accumulation in normal bone of mice compared with 99mTc-





showed the same degree of accumulation in
a osteogenic lesion of tumor-bearing rat models. Thus, the
uptake ratio of osteogenic lesion to normal bone (osteogenic





was higher than that of 99mTc-MDP. The authors supposed
that the higher osteogenic lesion/normal bone ratio derived
forms the higher molecular size, which was determined









In 2013, we reported 67Ga-DOTA-conjugated l-Asp pep-
tides (67Ga-DOTA-(Asp)
𝑛
, Figure 7(c)), which had varying
peptide lengths (𝑛 = 2, 5, 8, 11, or 14) [57]. Binding affinity
to HA of 67Ga-DOTA-(Asp)
𝑛
increased with an increase in














































































Figure 8: Chemical structures of carbon-11 labeled cathepsin K inhibitors: (a) 2-cyano-4-(cyclohexylamino)-N-(4-[11C]methoxyphenethyl)-
pyrimidine-5-carboxamide and (b) 2-cyano-N-(4-[11C]methoxyphenethyl)-4-(neopentylamino) pyrimidine-5-carboxamide.
the length of the aspartate peptide. The HA binding of 67Ga-
DOTA-conjugated bisphosphonate, 67Ga-DOTA-Bn-SCN-
HBP, was inhibited by lower concentrations of alendronate,
one of bisphosphonate compounds, compared with 67Ga-
DOTA-(Asp)
14








selectively and highly accumulated in bone
(10.5 ± 1.5, 15.1 ± 2.6, and 12.8 ± 1.7% ID/g, resp.). Although
the bone accumulation of 67Ga-DOTA-(Asp)
𝑛
was lower
than that of 67Ga-DOTA-Bn-SCN-HBP, the blood clearance
of 67Ga-DOTA-(Asp)
𝑛
was more rapid. Accordingly, the





were comparable to that of 67Ga-DOTA-Bn-SCN-
HBP. Moreover, the inhibition of radioactive bone accumu-
lation by alendronate was greater after injection of 67Ga-
DOTA-Bn-SCN-HBP than that of 67Ga-DOTA-(Asp)
14
.
These results indicate that not only bisphosphonate
molecules but also acidic amino acid peptide sequences could
be useful as carriers of radionuclides to bone metastases
lesions. Moreover, radiometal complex-conjugated acidic
amino acid peptides may provide slightly different informa-
tion from radiometal complex-conjugated bisphosphonates.
6. Carbon-11 Labeled Cathepsin K Inhibitors
Cathepsin K is a member of the papain family of cysteine
peptidases with a primary physiological function of cleavage
of type I and type II collagen [58]. The enzyme is highly
expressed in activated osteoclasts, and a change in the
number of the osteoclast is related to bone diseases such as
osteoporosis [59]. Therefore, it could be useful to determine
the changes in osteoclast numbers in such disease states by
imaging cathepsin K. Becausemany inhibitors of cathepsin K
have been synthesized and evaluated both in vitro and in vivo,
their derivatives may be candidates as mother compounds
for cathepsin K imaging agents. The possibility of targeting
cathepsin K in in vivo imaging, using a near-infrared reporter
probe, was confirmed in a previous report [60].




















































M = Tc or Re
(b)
Figure 9: Chemical structures of a heptamethine indocyanine-type NIR fluorophore conjugated bisphosphonate: (a) Pam78 and a
trifunctional diagnostic agent and (b) Pam-Tc/Re-800.
Rodnick et al. reported carbon-11-labeled cathepsin K
inhibitors with high affinity as cathepsin K imaging agents, 2-
cyano-4-(cyclohexylamino)-N-(4-[11C]methoxyphenethyl)-
pyrimidine-5-carboxamide ([11C]1, Figure 8(a)) and 2-
cyano-N-(4-[11C]methoxyphenethyl)-4-(neopentylamino)
pyrimidine-5-carboxamide ([11C]2, Figure 8(b)) in 2014
[61]. Nonradioactive counterparts of [11C]1 and [11C]2 were
reported in 2007 [62]. In that study, because the pyrimidine
core structure docked into the cathepsin K active site, many
types of derivatives based on a pyrimidine scaffold were
synthesized and evaluated as cathepsin K inhibitors. Among
them, the nonradioactive counterparts showed greater
affinity and selectivity for cathepsin K. For inhibition of
cathepsin K, cathepsin L, and cathepsin S, IC
50
values of
compound 1were 0.022, 0.17, and 0.7, and those of compound
2 were <0.003, 1.2, and 0.9, respectively. [11C]1 and [11C]2
were radiosynthesized by standard reaction conditions used
for alkylation reactions with [11C]methyl iodide. In vivo
𝜇-PET imaging experiments showed that [11C]1 and [11C]2
inhibitors have a higher uptake in actively growing bone
regions, such as distal ulnar, carpal, distal and proximal
humeral, distal femur, and proximal tibia, than in nontarget
regions such as muscle. The uptake in specific bone regions
was based on specific binding to cathepsin K because the
uptake was inhibited by pre- or coinjection of an excess
amount of ligands. These results indicated that radiolabeled
cathepsin K inhibitors could have potential as in vivo imaging
agents to determine a change in the number of osteoclasts.
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7. Dual-Modality Single Photon Emission
Computed Tomography/Near-Infrared
(SPECT/NIR) Fluorescent Probe
Recently, multimodality molecular imaging combining sev-
eral imaging techniques has attractedmuch attention in basic
scientific and clinical research. Nuclear medical imaging can
detect deep tissues in the body with high sensitivity, but there
are some problems such as relatively poor spatial resolution
[63].
Optical imaging is a relatively new imaging modality
that offers real-time and nonradioactive and high-resolution
imaging of fluorophores in lesion sites, but it is difficult to
detect a deep tissue using this technique [64]. Fluorescence
imaging with near-infrared (NIR, 700–900 nm wavelength)
light reveals relatively low tissue absorption. IRDye78 is a
heptamethine indocyanine-type NIR fluorophore with peak
absorption at 771 nm and peak excitation emission at 806 nm.
Pam78 (Figure 9(a)), a IRDye78-conjugated pamidronate
(one of the bisphosphonate derivatives), has been reported as
a NIR fluorescence imaging probe targeted to HA [65]. HA
is considered to be a good marker for some diseases because
calcification (HA deposition) occurs during the processes of
cancer and atherosclerosis.
Bhushan et al. reported the trifunctional diagnostic agent
Pam-Tc/Re-800 (Figure 9(b)) in 2008 [66]. Pam-Tc/Re-800
possesses a radiometal complex as a nuclear imaging probe, a
fluorescent site as a fluorescence imaging probe, and bispho-
sphonate having high affinity for HA as a carrier to bone in a
molecule. In an in vitro experiment, Pam-Tc/Re-800 showed
specific and selective binding to HA. In the fluorescence
imaging of microcalcified breast cancer rat model, Pam-Re-
800 detected breast cancer microcalcifications. In SPECT/CT
imaging, Pam-Tc-800 showed not only accumulation in nor-
mal bone but also highly sensitive detection of breast cancer
microcalcifications. In biodistribution experiments, the total
body clearance of Pam-Tc-800 at 4 hours after injection was
comparable to that of 99mTc-MDP. Moreover, Pam-Tc-800
showed a higher uptake in bone and tumor than 99mTc-
MDP. These results indicated that the novel trifunctional
agent could provide simultaneous imaging by SPECT and
NIR fluorescence. Dual-modality imaging may compensate
for the drawbacks of the other modalities.
8. Summary
In this paper, several well-designed bone-seeking compounds
were reviewed. They are chemically well-characterized and
different from 99mTc-MDP and 99mTc-HMDP. Some demon-
strated superior biodistribution characteristics. The mech-
anism by which all the compounds (except the carbon-
11 labeled cathepsin K inhibitors) accumulate in bone
is derived due to a high affinity for HA. We estimate
that 68Ga-DOTA-conjugated bisphosphonate compounds,
such as 68Ga-BPAMD and 68Ga-DOTA-Bn-SCN-HBP, are
the most promising diagnostic agents for bone metastases
because they show superior biodistribution characteristic and
68Ga is a useful PET radionuclide in clinical. Moreover, as
DOTA ligand could form a complex with not only 67/68Ga but
also 177Lu and 90Y, the palliation therapy is applicable using
the same ligand. Namely, this system is “theranostics”, which
is a combination of diagnosis and therapy.
Thus, the information from imaging data and the type of
bone metastasis susceptible to treatment should be similar
to those for existing bone-seeking radiopharmaceuticals. We
hope that novel bone-seeking compounds that possess a
different accumulation mechanism will be developed in the
near future.
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